Evidence map›Paper›PMID 30545939›Full record

ArticleThe Journal of biological chemistry2019

Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding.

Aruna Bitra, Tzanko Doukov, Giuseppe Destito, Michael Croft, Dirk M Zajonc

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. 4-1BB immunotherapy: advances and hurdles.Experimental & molecular medicine · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. An engineered 4-1BBL fusion protein with "activity on demand".Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Aruna BitraFrom the Division of Immune Regulation, La Jolla Institute for Immunology (LJI), La Jolla, California 92037.ORCID 0000-0003-1675-3544
Tzanko Doukovthe Stanford Synchrotron Radiation Lightsource, SLAC, Menlo Park, California 94025.ORCID 0000-0001-8625-2572
Giuseppe DestitoKirin Kyowa Hakko Pharmaceutical Research, La Jolla, California 92037.
Michael CroftFrom the Division of Immune Regulation, La Jolla Institute for Immunology (LJI), La Jolla, California 92037.
Dirk M ZajoncFrom the Division of Immune Regulation, La Jolla Institute for Immunology (LJI), La Jolla, California 92037, dzajonc@lji.org.ORCID 0000-0001-7215-1981
La Jolla Institute for Immunology · USKirin (United States) · USStanford Synchrotron Radiation Lightsource · US

Funding

X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
Structural Characterization of 4-1BB-Galectin-9 ComplexesR03AI110929 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL, ZAJONC, DIRK M · 2014 to 2015
$177k
NIAID NIH HHS R03 AI110929NIGMS NIH HHS P41 GM103393
6 · The paper itself

Abstract

The interaction between the receptor 4-1BB and its ligand 4-1BBL provides co-stimulatory signals for T-cell activation and proliferation. However, differences in the mouse and human molecules might result in differential engagement of this pathway. Here, we report the crystal structure of mouse 4-1BBL and of the mouse 4-1BB/4-1BBL complex, which together provided insights into the molecular mechanism by which m4-1BBL and its cognate receptor recognize each other. Unlike all human or mouse tumor necrosis factor ligands that form noncovalent and mostly trimeric assemblies, the m4-1BBL structure formed a disulfide-linked dimeric assembly. The structure disclosed that certain differences in the amino acid composition along the intramolecular interface, together with two specific residues (Cys-246 and Ser-256) present exclusively in m4-1BBL, are responsible for this unique dimerization. Unexpectedly, upon m4-1BB binding, m4-1BBL undergoes structural changes within each protomer; moreover, the individual m4-1BBL protomers rotate relative to each other, yielding a dimerization interface with more inter-subunit interactions. We also observed that in the m4-1BB/4-1BBL complex, each receptor monomer binds exclusively to a single ligand subunit with contributions of cysteine-rich domain 1 (CRD1), CRD2, and CRD3. Furthermore, structure-guided mutagenesis of the binding interface revealed that novel binding interactions with the GH loop, rather than the DE loop, are energetically critical and define the m4-1BB receptor selectivity for m4-1BBL. A comparison with the human 4-1BB/4-1BBL complex highlighted several differences between the ligand- and receptor-binding interfaces, providing an explanation for the absence of inter-species cross-reactivity between human and mouse 4-1BB and 4-1BBL molecules.

Indexed as

Protein Multimerization4-1BB LigandAnimalsHEK293 CellsHumansMiceMultiprotein ComplexesProtein DomainsProtein Structure, QuaternarySf9 CellsSpodopteraTumor Necrosis Factor Receptor Superfamily, Member 94-1BB LigandMultiprotein ComplexesTNFRSF9 protein, humanTumor Necrosis Factor Receptor Superfamily, Member 94-1BB4-1BB ligandCD137CD137Lcell surface receptorimmune cellprotein–protein interactionprotein structureTNFRSF9tumor necrosis factor (TNF)X-ray crystallography

Identifiers

PMID30545939
PMCPMC6369289
OpenAlexW2896844754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.